3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Completed
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Neoplasm Metastasis
1
Lung Neoplasms
1
Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene Fusion
1
Locally Advanced Thyroid Gland Carcinoma
1
Glioma
1
Diffuse Intrinsic Pontine Glioma
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Advanced or Recurrent Solid Tumor Harboring an NTRK Gene Fusion
1
Advanced Thyroid Cancer Patients Who Received Target Therapy
1
Interventions
Bevacizumab
77
Fluorouracil
55
Cetuximab
48
Oxaliplatin
43
Leucovorin
42
pembrolizumab
37
Irinotecan
33
Folfox protocol
24
Capecitabine
24
HMPL-013
22
Specimen Handling
19
trifluridine tipiracil drug combination
17
Panitumumab
15
Blood Specimen Collection
15
Nivolumab
14
Magnetic Resonance Spectroscopy
14
regorafenib
13
Biopsy
13
Trifluridine
12
Gemcitabine
12
Cisplatin
12
Standard of Care
11
sintilimab
10
Interviews as Topic
10
IFL protocol
10
Drug Therapy
10
Carboplatin
10
Cyclophosphamide
9
tislelizumab
8
Trastuzumab
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Colorectal Neoplasms
×
larotrectinib
×
Clear all
NCT05725200
2023-02-21
EVIDENT
Oslo University Hospital
Phase 2
Recruiting
40 enrolled